This site is intended for Healthcare Professionals only

GLP-1 prescribing in Scotland increased by 430 per cent over five years

The ABPI found 265 per 100,000 GP-registered population were prescribed a GLP-1 receptor agonist.

Prescribing of GLP-1 medicines across NHS boards in Scotland increased by around 430 per cent over a five-year period, according to an analysis by the Association of the British Pharmaceutical Industry (ABPI).

The analysis found 50 per 100,000 GP-registered population were prescribed a GLP-1 receptor agonist, GIP or GLP-1 dual receptor agonist in September 2020 but by August 2025, that had risen to more than 265 per 100,000.

The analysis was based on routinely collected community and hospital prescribing data. The ABPI stressed the research does not distinguish between prescribing for type 2 diabetes and prescribing for weight management, while private prescribing was not captured. 

It said prescribing increased to about 125 per 100,000 by the end of 2022 “before declining and stabilising through to mid-2024 and then rising rapidly”.

The ABPI said the Western Isles and Greater Glasgow and Clyde recorded the highest prescribing rates “despite differing substantially in recorded population need”.

That was despite Greater Glasgow and Clyde having the second-lowest prevalence of overweightness and obesity across NHS boards, while the Western Isles had the second-highest prevalence but the fourth-lowest diagnosed diabetes prevalence.

Shetland had the lowest per-capita prescribing despite “relatively high overweight and obesity prevalence”, the report added. The Western Isles recorded the highest three-month average prescribing with around 10 times the rate in Shetland.

However, the ABPI said: “This comparison should be interpreted cautiously because the small populations of island boards mean that relatively small changes in absolute quantities can produce large per-capita movements.”

Describing “the combined burden of type 2 diabetes, overweight and obesity” as “a substantial and growing public health challenge in Scotland”, the ABPI said its overall findings revealed “strong growth in NHS prescribing of GLP-1 and GIP/GLP-1 therapies, alongside substantial geographical variation”.

“Patient pathways, specialist capacity, referral criteria and prescriber confidence are likely to be important in translating national advice into routine use,” the ABPI said.

It added: “Crucially, the findings should not be interpreted as evidence of widespread NHS adoption for obesity. The data is likely to predominantly reflect prescribing for type 2 diabetes, while obesity implementation has been more restricted, phased and locally dependent.”

Share:

Change privacy settings